Neurogene Inc. (NGNE) company profile
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
About Neurogene
Pharmaceutical Preparations, SIC 2834
Neurogene Inc. is a clinical-stage biotechnology company that creates genetic therapies for individuals with severe and rare neurological disorders. The company's primary focus is developing treatments using its proprietary transgene regulation platform, which controls therapeutic protein expression in targeted cells. Its leading clinical asset, NGN-401, is an adeno-associated virus gene therapy designed to treat female pediatric and adult patients suffering from Rett syndrome. The firm operates in the biopharmaceutical sector without commercialized products, directing its investigative programs toward patients and healthcare systems that manage life-threatening central nervous system illnesses.
The organization operates an internal good manufacturing practice facility measuring 42,000 square feet in Houston, Texas, which encompasses process and analytical laboratories along with 6,000 square feet of dedicated cleanroom space. It also maintains an academic research collaboration with the University of Edinburgh. The business employs 131 full-time personnel, including 106 staff members in research, development, and technical operations, with approximately 78 workers situated at the Texas production site.
Summary of the business section of Neurogene's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Neurogene Inc.
- Founded
- 2018
- Headquarters
- New York, NY
- Address
- 535 W 24th Street, 5th Floor 10011
- Phone
- (877) 237-5020
- Website
- neurogene.com
- Employees
- 131, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Morristown, NJ
Stock & identifiers
- Ticker
- NGNE
- Former tickers
- NLTX until Dec 19, 2023; AQXP until Nov 13, 2019
- Exchange
- Nasdaq
- IPO date
- Mar 7, 2014
- Shares outstanding
- 20M, Aug 7, 2026
- Public float
- $145.98M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Dec 19, 2023; 1-for-5 reverse, Sep 25, 2023
- SEC CIK
- 1404644
- CUSIP
- 64135M105
- ISIN
- US64135M1053
- FIGI
- BBG005Y0QDK1
- Share class FIGI
- BBG005Y0QF99
- LEI
- 529900A7VIY892SZVW73
- EIN
- 98-0542593
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rachel McMinn | Chief Executive Officer, Director | 1,345,063 |
| Christine Mikail Cvijic | President and CFO, Director | 84,040 |
| Christina Shafer | Chief Commercial Officer | – |
| Julie Jordan | Chief Medical Officer | 12,472 |
| Stuart Cobb | Chief Scientific Officer | 30,497 |
| Keith Woods | Director | – |
| Sarah B. Noonberg | Director | – |
| Rohan Palekar | Director | – |
| Robert Baffi | Director | – |
| Cory S. Freedland | Director | – |
| Robert Keith Woods | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Drachman | $0 | $0 | $2.11M | $202 | – |
| FY2025 Dr.Mc Minn | $3.21M | $3.23M | $2.11M | $202 | – |
| FY2025 Ms.Cochener | $0 | $0 | $2.11M | $202 | – |
| FY2024 Dr.Drachman | $0 | $0 | $2.91M | $225 | – |
| FY2024 Dr.Mc Minn | $3.46M | $2.72M | $2.91M | $225 | – |
| FY2024 Ms.Cochener | $0 | $0 | $2.91M | $225 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Rachel McMinn Founder and Chief Executive Officer | $618.80K | $371.28K | $385.75K | $1.83M | $7.16K | $3.21M | -7% |
| Christine Mikail President and Chief Financial Officer | $556.00K | $305.80K | $327.64K | $1.55M | $12.26K | $2.75M | -18% |
| Julie Jordan Chief Medical Officer | $496.80K | $198.72K | $135.58K | $640.39K | $819 | $1.47M | -40% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 7, 2014
- Offer price
- $11.00
- Securities offered
- 4,200,000
- Gross proceeds
- $46.20M
- Exchange
- Nasdaq
- First trading day
- Mar 7, 2014
- First-day close
- $11.95+8.6%
- Lock-up ends (est.)
- Sep 3, 2014
“The initial public offering price is $11.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 16, 2026, we had 131 employees, all of whom were employed full time and 106 of whom were engaged in research, development and technical operations activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 14, 2024 | Late filing | Notification of late filing |
| Dec 19, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 6, 2023 | Name change | Name changed from Neoleukin Therapeutics, Inc. to Neurogene Inc. |
| Aug 21, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 31, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 20, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 12, 2019 | Name change | Name changed from AQUINOX PHARMACEUTICALS, INC to Neoleukin Therapeutics, Inc. |
| Aug 12, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 7, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 3, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 24, 2013 | Name change | Name changed from AQUINOX PHARMACEUTICALS (USA) INC to AQUINOX PHARMACEUTICALS, INC |
See a number that looks wrong?